Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary) ; Prednisolone; Prednisolone; Prednisone; Prednisone
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms LIBERTY ASTHMA VOYAGE; VOYAGE
- Sponsors Sanofi
- 26 Feb 2024 Results of post-hoc analysis evaluating the association between lung function improvements and asthma control presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 09 Feb 2024 According to a Sanofi media release, post hoc analysis data from this trial will be presented at the American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting from February 23 to 26.
- 12 Sep 2023 Results assessing impact of dupilumab on asthma control and health-related quality of life (HRQoL) in children and their caregivers, published in the European Respiratory Journal